Long‐term preservation of kidney function with SGLT ‐2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease
Main finding · eGFR declineResult — go to the resultMean difference 1.43 mL/min/1.73 m²Authors' conclusion
In this large, real-world cohort, initiation of SGLT2i was associated with a significantly slower decline in kidney function and improved albuminuria compared with other diabetes drugs, including GLP-1RA. These findings support SGLT2i as the most effective T2D treatment to slow CKD progression.
Study context
- Population
- Patients aged 18–80 years with T2D and chronic kidney disease (CKD) who initiated an SGLT2 inhibitors (SGLT2i) or other glucose-lowering medications (GLM) between 2015 and 2020; mean age 63 years, BMI 32 kg/m², HbA1c 8.2%matched cohort
- Participants
- 2,020 vs 2,020
- Exposure
- SGLT2i vs other glucose-lowering medications
- SGLT2in = 2,020
- Other GLMn = 2,020reference
- Outcome
- Change in eGFR over time
Methodological detailsmulticentre, propensity-score matched, real-world
- Multicentre
- Propensity-score matched
- Real-world
Main finding
eGFR decline
Mean difference
1.43 mL/min/1.73 m²
P = 0.048
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Estimate | P value |
|---|---|---|
| Albuminuria category improvementSGLT2i vs Comparators · greater likelihood of improvement with SGLT2i | HR 1.17 | P = 0.007 |
| ≥40% eGFR reductionSGLT2i vs Comparators | HR 0.63 | P = 0.004 |
| eGFR slope, SGLT2i vs GLP-1RA subgroup (n = 1266/group)Better eGFR slope with SGLT2i | mean difference 0.62 mL/min/1.73 m²/year | P = 0.046 |
Original publication
Long‐term preservation of kidney function with SGLT ‐2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. Published 2 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →